propose that commitment to the regulatory T cell lineage is not dictated by the specificity of the precursor, but that recognition of agonist ligand expressed by thymic epithelium substantially enhances their positive selection.
Introduction
T-lymphocyte tolerance to self-antigens is induced in the thymus during the process of negative selection (1) . Despite the quantitatively impressive nature of this process (2), significant numbers of auto-specific T cells migrate to the periphery (3). In the periphery, autospecific T cells are kept silent by recessive (induction of apoptosis or anergy) and dominant tolerance mechanisms (4) . Dominant or "active" tolerance is assured by regulatory/suppressor T lymphocytes. The best characterized regulatory T cell (Treg) subset consists of CD4 + T cells expressing high levels of CD25, GITR, CTLA-4, and the forkhead/winged helix transcription factor Foxp3 (5-7). While for practical purposes (i.e. isolation of Treg) the best marker is CD25, Foxp3 expression appears to correlate best with regulatory function (8) . CD4 + CD25 + Treg play a major role in the prevention of autoimmunity (5, 6) and inflammatory bowel disease (9) , in regulating immunity to viral and parasite infections (10) , in maintenance of maternal tolerance to the fetus (11) , and in inhibition of anti-tumor immunity (12) .
Interestingly, the normally diverse CD4 + CD25 + regulatory thymocyte population selected on naturally expressed ligands, has higher avidity for self than CD4 + CD25 -cells (13) , resulting in a peripheral Treg repertoire highly enriched in self-reactive cells (14) (15) (16) . These observations raise important questions concerning the selection of these cells in the thymus. In this organ, (17) . Surprisingly, Treg precursors have been shown to be susceptible to thymic negative selection (14, 17, 18) . However, while autospecific Treg precursors are negatively selected by APC of bone marrow origin (14) , they appear relatively resistant to negative selection induced by thymic epithelium (TE, refs. (13, 19) . Therefore, TE plays an important role in
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development of dominant tolerance, as previously postulated based on the observation that TE can induce dominant transplantation tolerance (20) .
The precise role of positive selection in development of Treg remains unclear. It has been proposed that interaction with agonist ligands directs developing thymocytes to the Treg lineage.
However, studies with mice doubly transgenic for TCR and agonist ligand have led to conflicting results. In some cases, evidence of increased selection of CD4 To gain insight in the mechanisms of thymic Treg differentiation, we analyzed the role of agonist ligands expressed by TE in development of Treg-precursors with a naturally diverse TCR-repertoire. We generated bone-marrow chimeras in which superantigen (sAg)-presentation is limited to TE, and analyzed development of sAg-specific Treg. Our results indicate that agonist ligands considerably enhance positive selection of Treg.
Materials and Methods

Mice
All mice were used at 6 to 10 weeks of age. C57BL/6 and DBA/2 mice were purchased from 
Antibodies
The following antibodies were used for phenotypic analysis: FITC-labeled anti-TCR Vβ 3, -4, -5, -6, -14, -17 a , PE-labeled anti-CD25, PE-Cy7-labeled anti-CD4 (BD Pharmingen, San José, CA), PE-labeled anti-Foxp3 , APC-labeled anti-CD8 and anti-CD25 antibodies (eBioscience, San Diego, CA).
Flow Cytometry
Thymi were homogenized, washed in medium, and resuspended in 2.4G2 (anti-FcγR mAb, depletion was verified in every experiment and was routinely >99%.
Bone marrow chimeras
Irradiation bone marrow chimeras were generated by lethally irradiating (8.5 Gy γ) C57Bl/6
hosts using a 137 Cs source (7 Gy/min). Next day, irradiated mice were reconstituted by i.v.
injection of 10 7 bone marrow cells. Chimeras were kept on antibiotic containing water (0.2% Bactrim, Roche, Basel, Switzerland) for the complete duration of the experiment.
Statistical analysis
Statistical significance of differences between subpopulations were assessed using Student's t test and is indicated as: ns, not significant (p≥0.05); * p<0.05; ** p<0.01; *** p<0.001.
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We next analyzed irradiation chimeras in which bone marrow derived cells did not express MHC molecules and therefore could not present sAg. As compared to B6→B6 and DBA/2→DBA/2 chimeras, in MHC°→B6 and MHC°→DBA/2 chimeras significantly increased percentages of CD4SP thymocytes were found (Fig. 1B) . These results are due to substantially reduced induction of apoptosis of autospecific cells in these chimeras, as previously reported (2 Control Vβ4 + and Vβ14 + thymocytes were not deleted.
As compared to MHC°→B6 chimeras, in MHC°→DBA/2 mice a substantial increase in the percentage of CD4SP CD25 high regulatory thymocytes expressing sAg specific Vβ3, Vβ5, and In contrast, sAg-specific Foxp3 -CD4SP thymocytes were either partially deleted (Vβ5 and 6) or not affected (Vβ3) by sAg presented by TE (Fig. 2C ).
The MHC° mice we used as bone-marrow donors were on the C57BL/6 background in which very few mouse mammary tumor virus genomes are present (30) . Since hematopoietic cells are known to produce sAg, sAg-presentation in MHC° → DBA/2 and DBA/2 → DBA/2 chimeras is not only qualitatively but also quantitatively different. One could therefore argue that enhanced positive selection of sAg-specific regulatory T cells in MHC° → DBA/2 chimeras might be due to the lower overall avidity of the interaction of thymocytes with stromal cells, independently of the nature (DC or TEC) of the presenting cell. To assess this possibility we generated MHC° → DBA/2 and B10.D2 → DBA/2 chimeras in which the expression-levels of sAg were the same but the nature of the cells presenting them differed. As shown in Fig. 2C -population therefore appears to be enriched in self-antigen specific T lymphocytes, as previously suggested (8, 38) .
SAg do not enhance positive selection of precursors for conventional T cells
The 
Discussion
This is the first study on the role of natural agonist ligands on Treg development in mice with a normally diverse TCR-repertoire. We found that sAg-specific Treg precursors were deleted in mice in which both TE and APC of bone-marrow origin presented sAg, as we have previously reported (14) . In contrast, in bone marrow chimeras in which sAg are exclusively expressed by TE, we found that development of sAg-specific Treg (but not conventional T cells) was substantially enhanced. Therefore, our data unambiguously show that agonist ligands substantially enhance development of Treg.
Specificity for sAg is determined by the Vβ-region expressed by T lymphocytes. In mice containing endogenous mouse mammary tumor viruses, sAg-specific thymocytes are deleted during T cell development in the thymus (reviewed in ref. (30) . We have previously reported that precursors for Treg are not an exception and are efficiently deleted during development (14) .
When sAg are only presented by TE, deletion of precursors for conventional T cells is much less efficient and tolerance is mediated by clonal anergy (41 presented here a substantially smaller fraction of precursors was involved. Indeed, the total thymocyte-numbers and percentages of CD4SP were similar in the two types of irradiationchimeras we compared. As compared to chimeras in which no sAg was presented, in chimeras in which sAg were presented only by TE substantially higher numbers of sAg-specific Treg developed. Since in our experimental model it is difficult to imagine how results could be due to homeostatic mechanisms, we conclude that recognition of agonist ligand substantially enhanced development of Treg.
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